Intralesional Platelet-Rich Plasma for Treating Chronic Peyronie’s Disease: A Single-Center Retrospective Cohort Study

<i>Background and Objectives</i>: Peyronie's disease (PD) is a chronic fibrotic disorder of the tunica albuginea causing penile deformity and sexual dysfunction. Platelet-rich plasma (PRP) has been proposed as a regenerative therapy with potential disease-modifying properties, but evidence of its use in chronic PD is scarce. This study evaluated the efficacy and safety of intralesional PRP injections in men with stable PD. <i>Materials and Methods</i>: A single-center retrospective cohort study was conducted including men with chronic PD treated with three weekly intralesional PRP injections (April 2022-April 2025). Inclusion required curvature stability for ≥6 months and absence of prior PD therapy. The primary outcome was a change in penile curvature at 4 weeks post-treatment. Secondary outcomes included plaque thickness (ultrasound), erectile function (IIEF-5), and safety (Clavien-Dindo grading). <i>Results</i>: Thirty-six men (mean age 61.2 ± 10.4 years) completed the treatment. Mean penile curvature decreased from 30.5 ± 7.3° to 24.2 ± 8.3° (Δ = -6.3°, 95% CI -7.7 to -5.3; <i>p</i> < 0.001); 25% achieved a ≥10° reduction. Mean plaque thickness declined from 3.25 ± 0.69 mm to 2.91 ± 0.76 mm (Δ = -0.34 mm; <i>p</i> < 0.001). IIEF-5 increased modestly (+1.1; <i>p</i> = 0.142). Only mild, transient adverse events occurred (pain 5.6%, hematoma 2.8%). <i>Conclusions</i>: Intralesional PRP was safe and yielded statistically significant but modest reductions in penile curvature and plaque thickness in chronic PD. Clinically meaningful improvement occurred in a minority of patients. These findings support keeping PRP investigational pending well-designed randomized controlled trials with standardized protocols and longer follow-up.